proposals for afatinib have been awarded funding: Matthew Fury, MD, PhD, Memorial Sloan-Kettering Cancer Center, “Phase I Study of Induction Chemotherapy with Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage III/IVB HPV Associated
Search Results
NCCN News
NCCN News
, Genentech/Roche) in metastatic breast cancer. The recommendation is as follows: Bevacizumab in combination with paclitaxel is an appropriate therapeutic option for metastatic breast cancer with the evidence designation 2A. The following footnote
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Lisa A. Gurski
plus cisplatin and paclitaxel, followed by adjuvant cisplatin and gemcitabine; the 5-year OS rate was 56%. 59 In RTOG 0233, 97 patients received twice-daily radiation with concurrent paclitaxel plus cisplatin or 5-FU plus cisplatin; the 5-year OS was
Value-Based Insurance Design: Aligning Incentives, Benefits, and Evidence in Oncology
Jonas A. de Souza, Mark J. Ratain, and A. Mark Fendrick
Novotny W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med 2004 ; 350 : 2335 - 2342 . 17 Sandler A Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab for non
Uterine Neoplasms
Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng
endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study [abstract] . 39th Annual Meeting of the Society of Gynecologic Oncologists ; Tampa, FL
Thymomas and Thymic Carcinomas
David S. Ettinger, Gregory J. Riely, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr, Stefan C. Grant, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Eric Rohren, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Douglas E. Wood, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
for thymoma. 20 , 88 , 89 However, nonanthracycline regimens (eg, cisplatin/etoposide [with or without ifosfamide], carboplatin/paclitaxel) may be useful for patients who cannot tolerate the more aggressive regimens. 89 , 90 For thymic carcinoma, the
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
update, the NCCN panel added a recommendation for atezolizumab/carboplatin/paclitaxel/bevacizumab (category 1) as first-line therapy for patients with metastatic nonsquamous NSCLC based on results of a recent phase III randomized trial (IMpower150). 78
Invasive Breast Cancer
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars
addition of neoadjuvant trastuzumab to paclitaxel followed by FEC chemotherapy (fluorouracil, epirubicin, and cyclophosphamide) was associated with an increase in the pathologic complete response rate from 26% to 65.2% ( P = .016). 107 Thus, the
Optimizing Systemic Therapy for Bladder Cancer
Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack
-positive disease to a regimen of paclitaxel, gemcitabine, and cisplatin (PGC) or observation. 25 The study ultimately showed a survival advantage with adjuvant PGC compared with observation (median not reached [NR] vs 26 months; P <.0009). Unfortunately, the
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer
Laura M. Spring, Yael Bar, and Steven J. Isakoff
(or preceded by) the THP regimen, with docetaxel often substituted by weekly paclitaxel for improved tolerability. The role of anthracyclines in the neoadjuvant treatment of HER2+ breast cancer has been a topic of discussion, given the increasing